SupremeCourt

  • Subscribe to our RSS feed.
  • Twitter
  • StumbleUpon
  • Reddit
  • Facebook
  • Digg

Friday, January 25, 2013

Patent Ambush: Big Pharma vs Generics

Posted on 12:45 AM by Unknown
The Economic Times (ET) reports that MNC drug firms have been deploying the RTI (Right to Information) route to launch aggressive patent ambushes against generic firms. 

I quote:

"Pharmaceutical multinationals have begun using the Right to Information law to launch pre-emptive legal action against local generic players to protect the market of patented drugs and delay the entry of low cost generic medicines in the 60,000-crore domestic drug market.

MNCs are using such information to sue generic firms even at a stage when their marketing approval is still pending or during the few months' window between the grant of approval and the actual product launch. This is a marked departure from their earlier strategy of launching patent infringement suit only after a generic firm rolled out a competing drug in the market."

Patent law suits are nothing new and quia timet actions are also prior art, so to speak. So nothing out of the ordinary here in using RTI information to sue, given that there is no other credible way to know if a generic manufacturer intends to launch a patented drug, than that of querying the DCGI (Drug Controller General of India) office and finding out.

Killing Promiscuous Injunctions?
 
But the mere factum of suing does not necessarily mean that big pharma is entitled to an injunction, much less an ex parte one. In a series of posts, Prashant, Rajeev and I reflect on the growing promiscuity of Indian courts in granting ex parte injunctions i.e. interim restraining orders that are passed without so much as hearing the other side.

Along with my students, I now plan to file a PIL (public interest litigation) soon requesting the Supreme Court to direct that no ex-parte restraining order be granted in any patent case, given that almost every patent case invariably involves a challenge to the very "validity" of the patent. How then can an order be passed without so much as hearing the other side? If any of you are interested in joining hands with us on this important fight, please email me.

Dispensing with Interim Injunctions

More controversially perhaps, I've advocated that Indian courts simply dispense with the "interim" phase and move directly to trial. The rationale is that the interim phase demands a "prima facie" evaluation of the merits of a dispute, which in a patent case,  can quickly convert to a rather lengthy evaluation, if one is serious about getting as close as possible to the right result. 

Any attempt to compress the prima facie evaluation phase is likely to yield wrong results i.e a patent found to be prima facie valid, ends up being struck down after trial, causing significant harm to generic competitors and more importantly to patients who are forced to contend with monopoly pricing till such time as the patent is finally knocked down!

My advocacy is not particularly fanciful, given that the Supremes have recommended something similar in at least two cases, given the extraordinary delays inherent in the so called "interim" phase. 

For those interested, an old paper of mine (presented at Kysuhu University) is available here (a significantly updated and revamped version of this paper will soon be published in a book edited by Professors Margo Bagley and Ruth Okediji).

Regulatory Opacity 

So back to the RTI route, which triggered the ET article. As I'd mentioned, its nothing out of the ordinary and one that we'd expect pharma patentees to deploy, given that our much maligned regulator (DCGI) is known more for its opacity and underhand dealings than its transparency. Don't take my word for it...read this scathing indictment by our Parliamentary committee which takes the DCGI to task for its unhealthy cosying up to both multinational and generic firms. 

Tellingly, as the report notes, most drug regulators begin their mission statement with an avowed objective of serving the public interest and ensuring the safety and efficacy of drugs. Our regulator on the other hand goes on record stating that its primary purpose is to "meet the demands and requirements of the pharmaceutical industry"! (see  pages 2-3 of the report: para 2.2). Great bedtime reading, and I'd recommend that at the very least, our readers subject this scathing report to a peek preview.

Back to the theme at hand. For those interested, I'd recommended that all drug marketing approval applications filed before the DCGI be published immediately on its website. Apart from making the DCGI more transparent and accountable, this would go a long way towards weeding unethical practices such as those deployed by Natco when it lied to the Delhi High Court and stated that it had no interest in the anti cancer drug Dasatinib, whilst at the same time having filed a drug application for a generic version of this drug before the DCGI. 

The Natco Defamation Suit

Had the DCGI been more transparent and uploaded all of its applications for drug approval, I'd have been spared the agony of a law suit. And the court might have been spared the agony of an unethical ride by a home grown pharmaceutical firm (Natco), that had just made news for its heroic efforts in standing upto a large multinational firm and procuring a monumental compulsory licensing order.

But then again, I'm glad they sued on such a weak case. Hopefully, we'll get an order that deters future corporate bullies from attempting to gag free speech (and dare I say, the truth)! For the record, I will continue writing and commenting on this case..all within the contours of the law of course and my constitutionally guaranteed freedom of speech. 

For those interested, my written statement countering Natco's non-sensical suit is here. This defence incorporates many of the arguments advanced by Prashant in his posts here and here.

ps: Each time I comment on a pharma patent issue, I get hit with the question: Which side are you on? I reiterate again that I'm not particularly fond of George Bush and his: "Either you're with us or you're against us" approach. 

I'd like to think that, as with the Novartis Supreme Court submission, I follow a strict issue based approach. While I come down on the side of the generics and/or patient groups on some issues, my conclusions end up favouring originator pharma companies on others. And once in a while, what I advocate ticks off both sides...perhaps a good place to be in for an academic, particularly one who advocates the middle path and holds the freedom of thought and expression very close to his heart..
Email ThisBlogThis!Share to XShare to FacebookShare to Pinterest
Posted in Compulsory Licensing, DCGI, defamation, Drug Regulation, ex parte, Indian Pharma, Injunction, Natco, natco defamation suit, Patent, patent infringement, Pharma | No comments
Newer Post Older Post Home

0 comments:

Post a Comment

Subscribe to: Post Comments (Atom)

Popular Posts

  • IPAB on Payyannur Ring
    [*S lightly long post] Background: The Intellectual Property Appellate Board (“ IPAB ”), in its recent order in SubhashJewellery v. Payyan...
  • Guest Post: Intermediary liability in defamation cases - Parle, Mouthshut & Visakha cases to clarify the law
    Chaitanya Ramachandran, who has blogged for us previously over here and here , has sent us this excellent guest post analyzing the extent of...
  • IP Research Assistant position at IIT, Madras
    Feroz Ali Khader, MHRD IP Chair at the Indian Institute of Technology (IIT) Madras, is looking for research assistants to work on various is...
  • Dorling Kindersley v. Sanguine Technical Publishers
    A recent Delhi High Court order passed on 21 January, 2013  with respect to copyright licensing has come to our notice. An analysis of the j...
  • Call for Papers: IIT Bombay and MHRD jointly announce the 2nd International Conference on Management of Intellectual Property and Strategy
    The readers may be interested to know that the Shailesh J. Mehta School of Management of IIT Bombay is geared up to host, in collaboration w...
  • SpicyIP Tidbit: ALCS August Distribution
    In the UK, the Authors' Licensing and Collecting Society is an organization run and owned by writers that collects money due to its mem...
  • Delhi HC rejects the "Hot News" Doctrine: A Summary
    The applicability of the Hot News doctrine was rejected recently in a landmark ruling delivered by Justice Bhat of the Delhi HC. This post i...
  • Satyajit Ray's sketches and copyright controversies
    A copyright row appears to have started between the Satyajit Ray Society and the Delhi Art Gallery, that is organising a countrywide exhibit...
  • Thalappakatti biryani trademark row
    The southern district of Dindigal in Tamil Nadu occupies a special place in the hearts of biryani lovers. In the late 1950s, one Nagasamy N...
  • Karnataka High Court temporarily restrains German company from exploiting trade secrets of Homag India
    Image from here In an interesting judgment dated 10th October, 2012 the Karnataka High Court, sitting at Bangalore, has passed an interim in...

Categories

  • 126 (1)
  • 3(d) (4)
  • 3(f) (1)
  • 3(i) (1)
  • 3(k) (2)
  • Academic Writing (1)
  • access (10)
  • access to food (1)
  • access to health (3)
  • AIA (1)
  • AIDS/HIV (3)
  • Antitrust (2)
  • Bajaj v LML (1)
  • Basmati Row (2)
  • Biological Diversity (5)
  • Biologics (2)
  • biopiracy (4)
  • biotech (7)
  • Bollywood (25)
  • Broadcasters Rights (5)
  • Budget (1)
  • business method patent (2)
  • Call for papers (2)
  • Cipla (2)
  • Comparative Advertising (4)
  • Competition law (8)
  • Compulsory Licensing (27)
  • condonation of delay (1)
  • Conference (4)
  • Constitution (12)
  • Contracts (1)
  • Controller's decisions (8)
  • Copyright (112)
  • Copyright Amendment Bill 2010 (23)
  • copyright board (4)
  • Copyright Exceptions (6)
  • copyright office (1)
  • Copyright Rules (2013) (5)
  • Copyright Societies (9)
  • Counterfeiting (1)
  • creativity (1)
  • Cross Retaliation (1)
  • csir (4)
  • d (1)
  • D.U. Photocopy Case (16)
  • Darjeeling Tea (3)
  • Data Exclusivity (2)
  • Database (1)
  • DCGI (2)
  • decompilation (2)
  • defamation (9)
  • Designs (3)
  • Designs Act (3)
  • Differential Pricing (2)
  • Dilution (1)
  • Disabilities (3)
  • Disability (2)
  • DMCA (2)
  • Doha Declaration (1)
  • Domain Names (2)
  • Draft Policy of the Indian Government (2)
  • DRM (1)
  • Drug Regulation (7)
  • education (12)
  • Enercon (1)
  • Enforcement (1)
  • EU (2)
  • ex parte (2)
  • exhaustion (3)
  • Exhaustion of Rights (2)
  • Fair Dealing (8)
  • Fair Use (11)
  • Federal Circuit (1)
  • Fees (3)
  • FICCI (7)
  • FRAND (2)
  • free trade agreement (3)
  • FTA (3)
  • G.I. Registry (4)
  • gene sequences (3)
  • Generic medicine (4)
  • Geographical Indication (14)
  • Gilead (1)
  • Glenmark (5)
  • Gopika (34)
  • Guest post (11)
  • guidelines (1)
  • GWU-CII (1)
  • Herceptin (1)
  • hot news (3)
  • ICANN (1)
  • incremental innovation (1)
  • independence (1)
  • india (5)
  • Indian Government (1)
  • Indian patent litigation (27)
  • Indian Pharma (35)
  • Injunction (10)
  • Innovation (7)
  • INTA (1)
  • Intermediaries (10)
  • internet (11)
  • Internet Access Providers (IAPs) (5)
  • Internet Censorship (7)
  • IP scholarship (3)
  • IP aware (4)
  • IP Course (3)
  • IP Education (1)
  • IP Policy (11)
  • IP update (4)
  • ip writing competition (1)
  • IPAB (34)
  • ipchair (1)
  • IPO (1)
  • IPRS (5)
  • IT Act (1)
  • Journal (2)
  • judicial independence (3)
  • Jurisdiction (1)
  • Kruttika (4)
  • Legal Education (3)
  • Legal Research Tools (1)
  • Legal Scholarship (2)
  • library (2)
  • Licensing (7)
  • Madhulika (20)
  • mathematical methods (1)
  • Media law (3)
  • medical method (1)
  • Merck (4)
  • mhrd ip chair (1)
  • Microsoft (3)
  • Middle Path (1)
  • Moral Rights (2)
  • Movies (18)
  • musical work (2)
  • nanotechnology (1)
  • Natco (3)
  • natco defamation suit (5)
  • natco vs bayer (4)
  • need for transparency (1)
  • Novartis (8)
  • Novartis patent case in India (11)
  • NPEs (2)
  • nujs (1)
  • NUJS Conference (2)
  • Obituary (1)
  • obviousness (7)
  • Off-Topic (2)
  • online course (4)
  • Open Access (6)
  • Open Source (2)
  • Opposition (3)
  • Parallel Imports (4)
  • Parliament (1)
  • passing off (5)
  • Patent (52)
  • Patent act (10)
  • patent agent (5)
  • patent agent exam (9)
  • patent agent exam qualifications (3)
  • patent infringement (5)
  • Patent Licensing (2)
  • Patent litigation (2)
  • Patent Office (19)
  • patent pool (3)
  • Patent Prosecution (7)
  • Patent rules (2)
  • Patent Strategies (8)
  • Patents (9)
  • pegasus (1)
  • Personality Rights (1)
  • Pfizer (1)
  • Pharma (18)
  • Piracy (5)
  • plagiarism (3)
  • Plant Variety Protection (2)
  • post grant (1)
  • Prashant (2)
  • Preventive Detention (1)
  • Price Control (6)
  • prior publication (1)
  • Privacy (3)
  • Prizes (1)
  • public health (3)
  • Public Interest (4)
  • Publicity Rights (4)
  • Publishing (3)
  • radio (2)
  • Rajiv (18)
  • Rectification Petition (2)
  • Rejection (1)
  • research (3)
  • reverse engineering (2)
  • revocation (4)
  • rip (1)
  • Roche (2)
  • Roche vs Cipla (1)
  • Royalty (2)
  • RTI (2)
  • Scholarship (4)
  • section 16 (1)
  • Section 3(d) (7)
  • section 8 (6)
  • shamnad (11)
  • Shan Kohli (4)
  • Shouvik Kumar Guha (30)
  • Smartphones/Tablets (2)
  • Social Innovation (1)
  • Software (10)
  • software enforcement (3)
  • software patent (3)
  • Special 301 Report (1)
  • Spicy Tidbits (6)
  • spicyip (1)
  • SpicyIP Accolades (1)
  • SpicyIP Announcements (9)
  • SpicyIP Case (1)
  • SpicyIP Cases (3)
  • spicyip commiseration (1)
  • SpicyIP Events (11)
  • SpicyIP Fellowship (5)
  • SpicyIP Guest Series (22)
  • SpicyIP Interview (2)
  • SpicyIP Jobs (4)
  • SpicyIP Jobs/General (2)
  • SpicyIP Review (1)
  • SpicyIP Tidbits (11)
  • SpicyIP Weekly Review (27)
  • Statutory Licensing (1)
  • STI Policy 2013 (4)
  • Sugen (3)
  • Supreme Court of India (5)
  • Swaraj (19)
  • Tarnishment (1)
  • Technology (6)
  • Technology Transfer (5)
  • TKDL (5)
  • TPP (1)
  • trade (4)
  • Trade Secret Protection (1)
  • Trademark (59)
  • Trademark dilution (1)
  • Trademark Registry (9)
  • Traditional Knowledge (7)
  • Transparency (5)
  • treaty (1)
  • trial (1)
  • tribunals (2)
  • TRIPS (11)
  • UK (3)
  • unfair competition (5)
  • UNFCCC (1)
  • Universities Research and Innovation Bill (2)
  • US (1)
  • US Patent Reform (1)
  • US Supreme Court (3)
  • viva (3)
  • WIPO (5)
  • Working a Patent (2)
  • Workshop (4)
  • writ (1)
  • WTO (1)

Blog Archive

  • ▼  2013 (364)
    • ►  September (13)
    • ►  August (41)
    • ►  July (36)
    • ►  June (36)
    • ►  May (32)
    • ►  April (51)
    • ►  March (66)
    • ►  February (40)
    • ▼  January (49)
      • The ‘Emcure model’ of Foreign Investment and Joint...
      • Patent Office makes public the feedback to the Dra...
      • SpicyIP Announcement: Brainstorming Session on Tra...
      • Locus standi and public interest under the GI Act ...
      • Spicy IP Weekly Review: January Weeks 2-3
      • Pirates of the Carribean: Retaliating Against IP
      • Delhi High Court clarifies the notification re pat...
      • Two years of continuing disappointment with the Ma...
      • Announcing the SpicyIP Fellows for 2013 - 2014!
      • Guest Post: Looking at IPR Policy in Climate chang...
      • Part I: Is decompilation of software legal under t...
      • Part II: Is decompilation of software legal under ...
      • Correction: Meerut scissors GI still in applicatio...
      • Guest Post: Graphene - Indian Patent filings disma...
      • Patent Ambush: Big Pharma vs Generics
      • Guest Post: For whom is the Indian IPR Regime?
      • Guest Post: More GI news as Meerut Scissors grante...
      • Guest Post: Taking a look at Online Piracy in India
      • Guest Post: Madurai Malli is granted GI status
      • SpicyIP Events: Workshop on Tools for Researching ...
      • INTA announces Annual Calendar of Events - 2013
      • Guest Post: Why are Business Method Patents being ...
      • Guest Post: Bare Licensing in India
      • Guest post: LAVA aims for 100 Mobile App Patents
      • SpicyIP Events: Patracode announces Workshop on To...
      • Samsung at the Supreme Court: Nationalising Exhaus...
      • Analysing Science, Technology and Innovation Polic...
      • Guest Post: Copyright in Social media - AFP v. Dan...
      • Open Access: What is it about?
      • The political economy of the current round of comp...
      • Guest Post: Examining the recently announced Compu...
      • The S(war)tz Legacy and "Open" Lessons for India
      • SpicyIP Events: Patracode announces Workshop on To...
      • Mark Lynas, former anti-GM food activist embraces ...
      • Rebutting ad hominem Twitter attacks
      • IP ideologies and the Swartz suicide
      • Aaron Swartz, RIP
      • Evading the mandatory royalty sharing provisions o...
      • DIPP to issue CLs for Herceptin, Dastinib & Ixabep...
      • SpicyIP Fellowship reminder
      • Introducing Science, Technology and Innovation Pol...
      • The Royalty Payment Siphon by MNCs - Independent D...
      • Introducing Science, Technology and Innovation pol...
      • SpicyIP Weekly Review: January (2013) Week 1
      • Incentives through Recognition? Nobel Assembly sue...
      • Guest Post: Plain Packaging Laws for Tobacco Products
      • Guest Post: Colours as Non-conventional Trademarks
      • FICCI announces online certificate course on Compe...
      • Guest Post: The Unfair Competition Act, 2011 and i...
  • ►  2012 (131)
    • ►  December (29)
    • ►  November (42)
    • ►  October (50)
    • ►  September (10)
Powered by Blogger.